UK
UK
Aug-10
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreMay-10
Gynecology and Obstetrics Healthcare Cost Musculoskeletal Women's Health
Read moreApr-10
Dermatology Healthcare Cost Rheumatology
Read moreMar-10
Jan-10
Gastroenterology Healthcare Cost Pharmacoepidemiology
Read moreMar-09
Healthcare Cost Pharmacoepidemiology
Read moreNov-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreNov-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreNov-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read moreSep-08
Endocrinology Healthcare Cost Pharmacoepidemiology
Read more| Date | Title | Categories | |
|---|---|---|---|
| Aug-10 | Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007 | Read more | |
| May-10 | Economic and Clinical Burden of Hip Fractures in Postmenopausal Women in the United Kingdom (UK) |
Gynecology and Obstetrics Healthcare Cost Musculoskeletal Women's Health |
Read more |
| Apr-10 | Estimation of Healthcare Costs as a Function of Disease Severity in People with Psoriatic Arthritis in the UK | Read more | |
| Mar-10 | Resource implications and budget impact of managing cow milk allergy in the UK | Read more | |
| Mar-10 | Do financial incentives for delivering health promotion counselling work? Analysis of smoking cessation activities stimulated by the quality and outcomes framework | Read more | |
| Jan-10 | The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK | Read more | |
| Oct-09 | Burden of Illness Study in Patients With Resistant Hypertension in UK | Read more | |
| Mar-09 | Prescribing Trends and Drug Budget Impact of the ARBs in the UK | Read more | |
| Nov-08 | Is Insulin Glargine a Cost Effective Option in Treatment of Patients with Type DM1 with Baseline HBA1C Above 8% in Comparison to NPH and Premix in Poland? | Read more | |
| Nov-08 | Cost-Utility of Insulin Glargine Compared to Pre Mix in Type 2 from Public Payer Perspective in Poland | Read more | |
| Nov-08 | Is Insulin Glargine a Cost-Effective Option for Treatment of Patients Naive to Insulin Treatment with Type 2, Baseline HBA1C Above 8% and Age Below 65 Years in Comparison to NPH and Premix in Poland? | Read more | |
| Sep-08 | The relative cost effectiveness of insulin glargine versus detemir insulin using UK real life data in patients with type 2 diabetes mellitus | Read more |
